| Hematopoietic Stem Cell Transplantation | Lifetime | 8 | FR 2 | 99.92 |
| Acute Lymphoblastic Leukemia research | Lifetime | 21 | FR 1 | 99.86 |
| Acute Myeloid Leukemia Research | Lifetime | 25 | FR 2 | 99.85 |
| Multiple Myeloma Research and Treatments | Lifetime | 44 | FR 4 | 99.70 |
| Protein Degradation and Inhibitors | Lifetime | 57 | FR 6 | 99.42 |
| Immune Cell Function and Interaction | Lifetime | 330 | FR 17 | 99.55 |
| Neutropenia and Cancer Infections | Lifetime | 51 | FR 3 | 99.38 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 92 | FR 4 | 99.46 |
| Polyomavirus and related diseases | Lifetime | 77 | FR 6 | 98.95 |
| T-cell and B-cell Immunology | Lifetime | 292 | FR 12 | 99.40 |
| CAR-T cell therapy research | Lifetime | 225 | FR 16 | 99.25 |
| Immunotherapy and Immune Responses | Lifetime | 614 | FR 23 | 99.01 |
| Peptidase Inhibition and Analysis | Lifetime | 634 | FR 24 | 97.88 |
| Childhood Cancer Survivors' Quality of Life | Lifetime | 464 | FR 8 | 97.82 |
| Cancer Treatment and Pharmacology | Lifetime | 676 | FR 49 | 98.22 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 295 | FR 16 | 97.78 |
| Renal Transplantation Outcomes and Treatments | Lifetime | 569 | FR 34 | 97.85 |
| Lymphoma Diagnosis and Treatment | Lifetime | 954 | FR 72 | 97.87 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 978 | FR 71 | 97.72 |
| Cytomegalovirus and herpesvirus research | Lifetime | 932 | FR 44 | 96.66 |
| Blood disorders and treatments | Lifetime | 405 | FR 22 | 95.54 |
| Histone Deacetylase Inhibitors Research | Lifetime | 640 | FR 21 | 94.65 |
| Hematopoietic Stem Cell Transplantation | 2021-2025 | 1 | FR 1 | 99.94 |
| Acute Lymphoblastic Leukemia research | 2021-2025 | 18 | FR 2 | 99.63 |
| Neutropenia and Cancer Infections | 2021-2025 | 9 | FR 1 | 98.67 |
| Acute Myeloid Leukemia Research | 2021-2025 | 44 | FR 3 | 99.52 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 30 | FR 6 | 99.61 |
| Protein Degradation and Inhibitors | 2021-2025 | 33 | FR 5 | 99.33 |
| CAR-T cell therapy research | 2021-2025 | 328 | FR 18 | 97.77 |
| Polyomavirus and related diseases | 2021-2025 | 51 | FR 6 | 96.26 |
| Immune Cell Function and Interaction | 2021-2025 | 375 | FR 11 | 95.36 |
| Cancer therapeutics and mechanisms | 2021-2025 | 102 | FR 3 | 92.89 |
| Blood disorders and treatments | 2021-2025 | 60 | FR 4 | 93.50 |
| T-cell and B-cell Immunology | 2021-2025 | 446 | FR 19 | 90.33 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 644 | FR 37 | 93.72 |
| Peptidase Inhibition and Analysis | 2021-2025 | 475 | FR 13 | 91.63 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 403 | FR 24 | 92.79 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 772 | FR 23 | 90.42 |
| Cancer Treatment and Pharmacology | 2021-2025 | 545 | FR 41 | 89.91 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 554 | FR 37 | 88.35 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 788 | FR 41 | 78.60 |
